A carregar...
Experience with regorafenib in the treatment of hepatocellular carcinoma
Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways. Regorafenib was the first agent to positively show significant survival advantage as a second-line therapy...
Na minha lista:
| Publicado no: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8165525/ https://ncbi.nlm.nih.gov/pubmed/34104211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562848211016959 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|